文献速递乳腺癌

比较伊曲康星聚乙二醇与医生选择方案治疗局部复发或转移性乳腺癌的健康相关生活质量:随机III期BEACON试验结果

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
PubMed 文献 · Eur J Cancer · 2017-03-27

BEACON试验纳入蒽环类、紫杉类和卡培他滨预处理的局部复发或转移性乳腺癌患者,随机接受伊曲康星聚乙二醇(145 mg/m² 每3周)或医生选择单药方案,分析733例患者健康相关生活质量。伊曲康星聚乙二醇在全球健康状况和躯体功能方面至32周显示有利差异(P<0.02),但两组在疾病进展时生活质量均下降。

要点

  • 伊曲康星聚乙二醇组在全球健康状况和躯体功能方面至32周优于医生选择方案(P<0.02)。
  • 伊曲康星聚乙二醇与胃肠道症状加重相关,医生选择方案与呼吸困难等全身副作用加重相关。
  • 疾病进展时两组生活质量均下降,全球健康状况平均较基线变化分别为-9.4和-10.8分。

核心结论

  • 与当前标准治疗药物相比,伊曲康星聚乙二醇在多个生活质量指标(包括全球健康状况和躯体功能)上显示获益证据,尽管胃肠道症状(如腹泻)更差。
  • 两组患者在疾病进展时生活质量均下降。

研究设计与样本

  • 随机III期BEACON试验(NCT01492101),纳入蒽环类、紫杉类和卡培他滨预处理的局部复发或转移性乳腺癌患者。
  • 852例患者中733例在随机后接受生活质量评估,伊曲康星聚乙二醇组378例(145 mg/m² 每3周),医生选择单药组355例。
  • 使用EORTC QLQ-C30(版本3.0)及QLQ-BR23评估,筛查时、治疗期间每8周及治疗结束时完成问卷。

主要发现

  • 全球健康状况和躯体功能量表在至32周时显示有利于伊曲康星聚乙二醇的差异(P<0.02)。
  • 其他功能量表报告数值上的改善。
  • 症状量表结果与不良事件谱一致:伊曲康星聚乙二醇与胃肠道症状加重相关,医生选择方案与呼吸困难和其他全身副作用加重相关。
  • 疾病进展时全球健康状况和躯体功能分析显示两组生活质量均下降,平均较基线变化分别为-9.4和-10.8分。

关键数值与推荐

  • 生活质量评分差异定义为≥5分,比较达到该差异的患者比例。
  • 全球健康状况和躯体功能至32周时组间差异P<0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Health-related quality of life (HRQoL) enhances understanding of treatment effects that impact clinical decision-making. Although the primary end-point was not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established etirinotecan pegol, a long-acting topoisomerase-1 (TOP1) inhibitor, as a promising therapeutic for patients with advanced/metastatic breast cancer (MBC) achieving clinically meaningful benefits in median overall survival (OS) for patients with stable brain metastases, with liver metastases or ≥ 2 sites of metastatic disease compared to treatment of physician's choice (TPC). Reported herein are the findings from the preplanned secondary end-point of HRQoL. PATIENTS AND METHODS: HRQoL, assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) (version 3.0) supplemented by the breast cancer-specific Quality of Life Questionnaire (QLQ-BR23), was evaluated post randomisation in 733 of 852 patients with either anthracycline-, taxane- and capecitabine-pretreated locally recurrent or MBC randomised to etirinotecan pegol (n = 378; 145 mg/m2 every 3 weeks (q3wk)) or single-agent TPC (n = 355). Patients completed assessments at screening, every 8 weeks (q8wk) during treatment, and end-of-treatment. Changes from baseline were analysed, and the proportions of patients achieving differences (≥5 points) in HRQoL scores were compared. RESULTS: Differences were seen favouring etirinotecan pegol up to 32 weeks for global health status (GHS) and physical functioning scales (P < 0.02); numerical improvement was reported in other functional scales. The findings from HRQoL symptom scales were consistent with adverse event profiles; etirinotecan pegol was associated with worsening gastrointestinal symptoms whereas TPC was associated with worsened dyspnoea and other systemic side-effects. Analysis of GHS and physical functioning at disease progression showed a decline in HRQoL in both treatment arms, with a mean change from baseline of -9.4 and -10.8 points, respectively. CONCLUSION: There was evidence of benefit associated with etirinotecan pegol compared with current standard of care agents in multiple HRQoL measurements, including global health status and physical functioning, despite worse gastrointestinal symptoms (e.g. diarrhoea). Patients in both arms had a decline in HRQoL at disease progression. STUDY NUMBER: NCT01492101.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Twelves C, Cortés J, O'Shaughnessy J, et al. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017. PMID: 28360015. doi:10.1016/j.ejca.2017.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。